National Executive Plan for the Cancer Control Program, 2014–2025

Objectives

The material outlines a national cancer-control framework focused on prevention, early detection, integrated treatment, palliative and psychosocial care, surveillance, research, patient participation and community partnership. A single overarching mission or quantified national goal is not clearly recoverable from all excerpts, but the identified priorities span the cancer pathway from risk reduction to follow-up and service improvement.[1][2][3][4][5][6][7][8]

• Reduce cancer-related risk factors through primary healthcare, prevention services, proposed well-being clinics, and clinical guidance that supports early identification of risks.[2]
• Prioritise early detection among high-risk groups, including breast cancer screening and an integrated mammography programme for women aged 40 to 65 years.[2]
• Strengthen healthcare capacity for cancer care through multidisciplinary secondary and tertiary services, workforce development, recognised palliative-care provision, and psychosocial rehabilitation incorporating relevant religious and spiritual support.[3]
• Establish two-way referral and feedback links between primary, secondary and specialist care.[4]
• Develop a comprehensive cancer database and surveillance capability to assess programme performance and cancer outcomes.[5]
• Prioritise epidemiological, clinical and cancer-economics research for priority cancer types, with findings intended to inform national guidance, decisions and interventions.[6]
• Strengthen participation by patients with cancer and their families in treatment follow-up, home care, palliative care and rehabilitation.[7]
• Promote community partnership by engaging governmental, private-sector and civil-society bodies in cancer control, while encouraging national private investment in related programmes.[8]

Implementation

Implementation combines prevention and screening in primary care with coordinated referral, multidisciplinary hospital care, data-driven surveillance, research, patient support and cross-sectoral partnership. The excerpts identify several operational actions and performance measures, but do not specify a complete national timetable, lead institution, formal governance hierarchy, consolidated budget, or financing allocations.[2][3][4][5][6][7][8]

• Provide periodic education for healthcare professionals on breast cancer signs and symptoms, and introduce training for personnel involved in health education, early detection and palliative care.[2][3]
• Implement mammography screening for women aged 40 to 65 years, maintain an early-detection register, and record detected cases, disease stage, screening coverage and response.[2]
• Establish well-being clinics and develop clinical guidelines for primary-care identification of cancer-related risk factors.[2]
• Complete integrated medical teams in secondary and tertiary care, recognise palliative care as a specialty, and develop palliative programmes covering psychological rehabilitation and religious or spiritual support.[3]
• Link primary, secondary and specialist services through referral and feedback arrangements that enable communication in both directions.[4]
• Collect cancer information from medical records, laboratories, radiology, pathology, nuclear medicine and death certificates across governmental and private facilities.[5]
• Assure data quality, conduct annual internal and external evaluation of surveillance indicators, and develop standards for quality and patient safety.[5]
• Monitor facility reporting, availability of routinely collected indicator data, registry completeness, data accuracy, surveillance coverage and survival for common cancers; track adherence to quality and patient-safety standards through service-performance indicators.[5]
• Form a specialised research team, identify priority cancer types, allocate a budget for approved studies, establish a timetable and implement the research programme. The source identifies this research-budget requirement but gives no amount, currency or funding source.[6]
• Evaluate research through completed studies, publication of findings on the economic burden of cancer treatment, national guidelines based on health-systems research, decisions informed by research, and interventions developed from such evidence.[6]
• Provide individual and group education for patients and families, home-care services, and guidance on home and palliative care; monitor participation, use of diagnostic, treatment and rehabilitation equipment, community-care staffing and adherence to programmes.[7]
• Establish joint activities among relevant organisations, define partnership foundations and organisational roles, include community representatives on national cancer-control committees, and encourage civil-society support and private-sector investment.[8]
• Track joint programmes, representation of governmental, private and civil-society organisations on national committees, private investment in health centres, and programmes benefiting from that investment.[8]

Monitoring & Evaluation

Monitoring and evaluation arrangements are unevenly recoverable across the supplied extracts. Earlier sections are substantially affected by OCR or extraction artefacts and do not provide a reliable overall framework for indicators, reporting, surveillance, evaluation or accountability.[9][10][11][12][13][14][15][16][17]More legible sections establish surveillance, service-delivery, workforce, research, patient-participation and community-partnership measures.[18][2][3][5][6][7][8]

• Use a surveillance system and survey-based monitoring, including the Global Youth Tobacco Survey, for tobacco-related work.[18]
• Monitor educational programmes for health professionals, establish an early-detection register, record detected cases, assess the distribution of cases by disease stage, and measure screening coverage and response.[2]
• Assess the number of well-being clinics and the availability of clinical guidelines supporting early identification of cancer-related risk factors.[2]
• Measure coverage of primary, secondary and specialised medical staff against international rates, and track the existence of training programmes and the annual proportion of trained personnel, including primary-care staff.[3]
• Monitor data submission by facilities, the share of indicators obtainable from routinely collected patient data, cancer-registry completeness, data accuracy and survival rates for common cancers.[5]
• Assess coverage of cancer-surveillance programmes and undertake annual internal and external evaluation of surveillance indicators.[5]
• Track compliance with quality and patient-safety standards through service-performance indicators.[5]
• Evaluate research through completed studies, publication of findings on the economic burden of cancer treatment, national guidelines based on health-systems research, decisions informed by this research, and interventional programmes based on it.[6]
• Monitor annual educational and home-care training programmes for patients and families, participation rates, access to diagnostic, treatment and rehabilitation equipment, numbers of community-care nurses and social specialists, and patient adherence to implemented programmes.[7]
• Assess patient and family participation in treatment follow-up and their performance in using relevant services.[7]
• Track representation of governmental, private-sector and civil-society bodies on national committees, the number of joint activities, private-sector investment in health centres, and the number of programmes benefiting from such investment.[8]

The available text does not specify a complete indicator dictionary, data definitions, reporting frequency, reporting channels, named bodies accountable for performance, or a consolidated evaluation design.[18][5][7][8]A 2010 epidemiological list provides baseline disease information, including breast cancer with 1,497 cases and 15.0%, colorectal cancer with 1,033 cases and 10.4%, non-Hodgkin lymphoma with 703 cases and 7.1%, thyroid cancer with 697 cases and 7.0%, and leukaemia with 616 cases and 6.2%.[19]It also lists liver cancer with 483 cases and 4.8%, lung cancer with 397 cases and 4.0%, Hodgkin disease with 336 cases and 3.4%, skin cancer with 319 cases and 3.2%, and stomach cancer with 291 cases and 2.9%.[19]

Costing & Financing

The extracts provide limited explicit financial information. They identify resource requirements for screening, well-being clinics, professional education, integrated multidisciplinary teams, palliative care, data systems, research and community-based support, but do not provide a consolidated cancer-control budget, costed implementation plan, quantified funding gap, financing allocation or economic assumptions.[2][3][5][6][7][8]

• Allocate a budget required to undertake approved cancer research studies after priorities, a timetable and studies have been determined. The amount, currency, funding source and period are not specified.[6]
• Encourage national private-sector investment in cancer-control programmes and monitor investment-related activity, including investment in health centres and programmes benefiting from it.[8]
• Provide qualified human resources, training, screening services, clinics and integrated care teams, although no costs or funding sources are specified for these inputs.[2][3]
• Develop information and surveillance systems spanning governmental and private facilities, including records, laboratories, radiology, pathology, nuclear medicine and death certificates, without an associated budget or financing mechanism.[5]

Numeric fragments in the earlier OCR-affected extracts cannot be reliably classified as costs, budgets or funding figures.[9][10][11][12][13][14][15][16][17]